Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis.

ABSTRACT:

Importance

Multiple systemic treatments are available for metastatic castration-sensitive prostate cancer (mCSPC), with unclear comparative effectiveness and safety and widely varied costs.

Objective

To compare the effectiveness and safety determined in randomized clinical trials of systemic treatments for mCSPC.

Data sources

Bibliographic databases (MEDLINE, Embase, and Cochrane Central), regulatory documents (US Food and Drug Administration and European Medicines Agency), and trial registries (ClinicalTrials.gov and European Union clinical trials register) were searched from inception through November 5, 2019.

Study selection, data extraction, and synthesis

Eligible studies were randomized clinical trials evaluating the addition of docetaxel, abiraterone acet

SUBMITTER: Wang L 

PROVIDER: S-EPMC7809610 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature